Publication: 2778

Publication: 2778

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

URL

URL

Google Scholar

Citation:: Blood vol 130 (Suppl 1) 2580

Meeting Instance:: ASH 2017
Year:: 2017
Type:: Abstract
Sub type:: Poster Discussion
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3367

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:: Novartis Pharma
Grants:: U10CA180821, U10CA180882, U10CA31946, U10CA180791, U10CA180820, U10CA180888, U24CA196171, U10CA180863, (CCSRI) 704970;

Corr. Author:
Authors:: Richard M. Stone Sumithra Mandrekar Ben L Sanford Susan Geyer Clara D. Bloomfield Konstanze Dohner Christian Thiede Guido Marcucci Francesco Lo-Coco Rebecca B. Klisovic Andrew Wei Jorge Sierra Miguel A. Sanz Joseph M. Brandwein Theo de Witte Dietger Niederwieser Frederick R. Appelbaum Bruno C. Medeiros Martin S. Tallman Jurgen Krauter *Richard F. Schlenk Arnold Ganser Hubert Serve Gerhard Ehninger Sergio Amadori Hartmut Dohner Richard A. Larson

Networks:: CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007

Study: CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: